Improving heart function in patients with hypertrophic cardiomyopathy
Official title: Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy
Funded at Boston Medical Center · NIH-11063988 · Data updated 2026-11-12
This study is looking at ways to improve how heart cells produce energy in people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle is too thick, to help slow down or even reverse the problems it causes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $716,458 |
| NIH project number | 5R01HL166606-02 |
| Project ID | NIH-11063988 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly those experiencing symptoms related to heart function.
✕Less likely to help
Patients without a diagnosis of hypertrophic cardiomyopathy or those with advanced heart failure may not benefit from this research.
What this research studies
This research investigates how to enhance mitochondrial function in patients with hypertrophic cardiomyopathy (HCM), a condition characterized by thickened heart muscle that can lead to heart failure. The study aims to understand the energy demands of heart cells and how mutations affect their ability to produce energy efficiently. By targeting the underlying energetic issues, the research seeks to delay or reverse the progression of HCM and its associated complications, such as diastolic dysfunction and arrhythmias.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart function and quality of life for patients with hypertrophic cardiomyopathy.
How similar studies have gone: Previous research has shown promise in targeting mitochondrial function to improve heart conditions, suggesting that this approach could be effective for hypertrophic cardiomyopathy as well.
Where this research is happening
-
Boston Medical Center
Boston, United States Active
Researchers
- Principal investigator: Luptak, Ivan — Boston Medical Center
- Study coordinator: Luptak, Ivan
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.